Business: PipelineWe continue to roll out and expand our pipeline
We continue to roll out and expand our pipeline
Parallel to to the clinical validation of our lead Fibrobody® in a pivotal imaging study, we are preclinically evaluating several of its therapeutic conjugates in preclinical studies.
Concurrently, we are loading our pipeline with novel Fibrobodies® that are directed against several established and experimental targets.
Pipeline
| Candidate | Disease | Discovery | Preclinical | Clinical phase I/II | Clinical phase II/III | |
|---|---|---|---|---|---|---|
Fibrobody®-Tracer Conjugate |
All fibrosis types |
In this pivotal imaging study we will validate the targeting ability of our lead Fibrobody® against PDGFRB, in patients suffering fibrosis. At the same time, the study will help us to identify those patients that would benefit most from Fibrobody-based therapy. |
||||
Fibrobody® Drug conjugate |
Liver fibrosis, Cirrhosis |
Our lead FDC program focuses on creating Fibrobody® Conjugates based on our lead Fibrobody® against PDGFRB, that carry potent anti-fibrotic drugs to activated myofibroblasts in the liver. |
||||
Fibrobody® |
Liver fibrosis, MASH |
This exciting program explores the use Fibrobodies® as vectors for highly effective therapeutic siRNAs. These entities are notoriously ineffective in reaching the intended cells. Fibrobody®-siRNA Conjugates may take the best of both worlds. |
||||
Fibrobody® Drug conjugate |
Idiopathic pulmonary hypertension |
This program focuses on creating Fibrobody® Conjugates that carry potent anti-fibrotic and anti-contractile drugs to activated myofibroblasts in pulmonary arterial hypertension, which is a severe and unmet medical need. |
||||
Fibrobody® Drug Conjugate |
undisclosed |
We are developing novel Fibrobodies® against established and experimental targets to complement and benchmark our lead Fibrobody® against PDGFRB |
||||
Oncobody® |
Fibrotic cancers |
This program explores the concept of using Fibrobodies® as vectors to carry potent cytytoxic drugs to activated myofibroblasts in fibrotic cancers, such as pancreatic adenocarcinoma. |
||||
Our lead Fibrobody®-Tracer Conjugate has entered clinical stage
We are presently rolling out a pivotal clinical imaging study in various types of fibrosis. The primary objective of this study is to validate the ability of our lead Fibrobody® to detect active, ongoing fibrosis in the clinical setting.
At the same time, the study will identify those patients and indications that would most benefit of Fibrobody-driven delivery of therapeutic payloads. This imaging-informed development approach greatly de-risks the development of any therapeutic Fibrobody®-Drug Conjugate.
In this study, we work closely together with leading clinical experts of Amsterdam University Medical Center.